Tech Company Financing Transactions
EyeBiotech Funding Round
EyeBiotech closed a $65 million Series A funding round on 3/11/2022. Backers included SV Health Investors, JEITO and MRL Ventures.
Transaction Overview
Company Name
Announced On
3/11/2022
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
71 Kingsway International Building
London, WC2B 6ST
UK
London, WC2B 6ST
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We created EyeBio to achieve a specific mission: to protect, restore, and improve vision for people living with eye diseases. Our work is urgent, because available therapies regularly fall short of improving vision or fail to provide durable, long-term solutions for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Guyer
Chief Medical Officer
Jonathan Prenner
Chief Operating Officer
Sarah Milsom
Vice President
Divya Manek
VP - Finance
Sam Smart
VP - Manufacturing
Paul Stephens
Browse more venture capital transactions:
Prev: 3/11/2022: A-Frame Brands venture capital transaction
Next: 3/11/2022: Timescale venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs